VKH
CRDF icon

Virtu KCG Holdings’s Cardiff Oncology CRDF Stock Holding History

Virtu KCG Holdings’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$14K Sell
153
-2,768
-95% -$178K ﹤0.01% 2753
2017
Q1 		$242K Buy
2,921
+2,478
+559% +$337K 0.01% 2204
2016
Q4 		$67K Buy
443
+253
+133% +$59.1K ﹤0.01% 3025
2016
Q3 		$61K Sell
190
-29
-13% -$10.6K ﹤0.01% 2753
2016
Q2 		$71K Sell
219
-435
-67% -$150K ﹤0.01% 2606
2016
Q1 		$219K Buy
+654
New +$223K 0.01% 2012
2015
Q2 		– Sell
-507
Closed -$248K – 3363
2015
Q1 		$248K Buy
507
+286
+129% +$122K 0.01% 2125
2014
Q4 		$68K Buy
221
+24
+12% +$7.77K ﹤0.01% 3351
2014
Q3 		$65K Sell
197
-53
-21% -$15.9K ﹤0.01% 3285
2014
Q2 		$63K Buy
+250
New +$80.1K ﹤0.01% 3394
2014
Q1 		– Sell
-306
Closed -$125K – 3584
2013
Q4 		$125K Sell
306
-659
-68% -$293K ﹤0.01% 3365
2013
Q3 		$496K Buy
+965
New +$550K 0.01% 2015

Other funds holding CRDF

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Virtu KCG Holdings's CRDF Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Cardiff Oncology (CRDF) stake by 95% in Q2 2017, selling an estimated $178K and leaving 153 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2753.

Virtu KCG Holdings first reported a position in CRDF in Q3 2013 and has held it in 12 quarters since. The position peaked at $496K in Q3 2013. 48 funds tracked by Wall St. Rank hold CRDF as of Q2 2017.

  • Virtu KCG Holdings held 153 shares of Cardiff Oncology worth $14K as of Q2 2017.
  • Virtu KCG Holdings sold 2,768 Cardiff Oncology shares in Q2 2017, an estimated $178K.
  • Cardiff Oncology made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2753 holding.
  • Virtu KCG Holdings first reported a position in Cardiff Oncology in Q3 2013 and has held it in 12 quarters since.
  • Virtu KCG Holdings's Cardiff Oncology position peaked at $496K in Q3 2013.
  • 48 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.